Loading
In this four-arm British trial, two months of chemotherapy before surgery for borderline resectable pancreatic cancer doubled the share of patients alive at one year compared with operating straight away, even though the same proportion got to an operation.
Multicentre randomised phase 2 trial of the European Study Group for Pancreatic Cancer in 90 patients with borderline resectable pancreatic ductal adenocarcinoma, randomised to immediate surgery or to one of three short-course neoadjuvant treatments (gemcitabine plus capecitabine, FOLFIRINOX, or capecitabine-based chemoradiotherapy) followed by surgery, with adjuvant chemotherapy in all arms.
Resection rates were similar between immediate surgery and the pooled neoadjuvant arms, but one-year overall survival was 39 percent after immediate surgery and 77 percent after neoadjuvant treatment (hazard ratio 0.27). The chemotherapy arms did better than chemoradiotherapy, and FOLFIRINOX did best.
ESPAC5 supports neoadjuvant chemotherapy over immediate surgery in borderline resectable disease and points to FOLFIRINOX as the regimen to build on.
Shares FOLFIRINOX / mFOLFIRINOX, Borderline resectable pancreatic ductal adenocarcinoma, Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Pancreatic ductal adenocarcinoma.
Shares ESPAC-5, FOLFIRINOX / mFOLFIRINOX, Borderline resectable pancreatic ductal adenocarcinoma, Capecitabine.
Shares FOLFIRINOX / mFOLFIRINOX, Borderline resectable pancreatic ductal adenocarcinoma, Capecitabine, Gemcitabine.
Shares Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Capecitabine, Gemcitabine, Pancreatic ductal adenocarcinoma.
Shares FOLFIRINOX / mFOLFIRINOX, Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Capecitabine, Gemcitabine.
Shares ESPAC-5, FOLFIRINOX / mFOLFIRINOX, Borderline resectable pancreatic ductal adenocarcinoma, Gemcitabine.
Shares ESPAC-5, FOLFIRINOX / mFOLFIRINOX, Borderline resectable pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
Shares ESPAC-5, Capecitabine, Gemcitabine, Pancreatic ductal adenocarcinoma.